SLNNCT06697054
Sentinel Lymph Node (SLN) Mapping With Charcoal Carbon Dye in Early Stage Cervical Cancer
At risk: Primary completion moved at least 2 years later, enrollment reduced 17%.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from May 12, 2026 to Jun 2028 Show 6 more changesShow less
- Enrollment reopened
- Eligibility criteria revised
- Enrollment reduced: 60 → 50 participants
- Study completion pushed from Jun 12, 2026 to Aug 2028
- Site details revised
- Publications: details revised at 4 of 4 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Detection rate of sentinel lymph node(s)
Timeframe: Two years
Specifity of sentinel lymph node mapping by carbon dye or ICG
Timeframe: Two years
Sensitivity of both tracers will be compared.
Timeframe: Two years
Arms and interventions
Two different tracers as a sentinel lymph node agent will be compared in early cervical cancerExperimental
Two different tracers, one charcoal carbon dye and other indocyanine used as sentinel lymph node agent will be compared in early cervical cancer in terms of detection rates, sensitivity, specificity, negative and positive predictive value. Both tracers will be used in the patient.
Diagnostic tests: Sentinel node biopsy with either ICG or carbon dye injection to cervix
Sites
1 site in 1 country
- Istanbul University Med Fac Dept. of Obstet and Gynecol. Division of Gynecologic OncologyIstanbul, Turkey, Turkey (Türkiye)